Mounjaro (Tirzepatide)
When Mounjaro arrived in 2022, it changed the conversation. Not because it was another GLP-1 medication — but because it wasn’t just a GLP-1 medication. It targets two hormone pathways instead of one, and the clinical trial results that followed made the entire field sit up and pay attention.
This page covers what Mounjaro is, what makes its dual-action mechanism genuinely different, what the research shows (including head-to-head data against semaglutide), and who it’s designed for. If you’re on Mounjaro or considering it, this is the full picture.
Mounjaro is the medication that made me realize this space was evolving fast. When the SURPASS trial data started coming out — showing weight loss numbers that rivaled dedicated weight management medications, from a drug approved for diabetes — it was clear this wasn’t just an incremental improvement. It was a different approach. Whether you’re taking it for diabetes or your doctor mentioned it as an option, understanding what makes tirzepatide unique helps you make sense of your own experience with it.
The Basics
Mounjaro is made by Eli Lilly. The active ingredient is tirzepatide — the same molecule used in Zepbound (Lilly’s weight management product). Same company, same drug, different approvals.
FDA-approved indications:
- Type 2 diabetes — to improve blood sugar control alongside diet and exercise (approved May 2022)
- Pediatric Type 2 diabetes — for children age 10 and older (approved December 2025)
What Mounjaro is NOT approved for: weight management. That’s Zepbound. If your primary goal is weight loss and you don’t have Type 2 diabetes, the Zepbound page covers the product designed for that purpose.
What Makes It Different: The Dual-Action Mechanism
Every other medication we’ve covered so far targets one hormone pathway — GLP-1. Mounjaro targets two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). You don’t need to remember that name, but you should know what it means.
Both GLP-1 and GIP are hormones your gut releases after you eat. They both help regulate blood sugar and appetite, but they do it through slightly different pathways. Think of it like having two people pushing the same boulder — each one contributes something the other doesn’t, and together they move it farther than either could alone.
This dual targeting is why tirzepatide’s trial results looked different from the semaglutide trials. It’s not just “more of the same” — it’s a fundamentally different pharmacological approach. The full science behind this lives on our Deep Dive: GLP-1 vs. Dual Agonists page if you want the deep cut.[1]
How It’s Delivered
Mounjaro comes as a single-dose, pre-filled pen — one injection per pen, then you throw it away. This is different from Ozempic’s multi-dose pen (where you dial your dose from the same pen for a month).
The Color-Coded System
Each dose has its own pen color, which makes it easy to confirm you’re using the right one:
| Dose | Pen Color | Volume |
|---|---|---|
| 2.5 mg | Gray | 0.5 mL |
| 5 mg | Purple | 0.5 mL |
| 7.5 mg | Green | 0.5 mL |
| 10 mg | Pink | 0.5 mL |
| 12.5 mg | Blue | 0.5 mL |
| 15 mg | Orange | 0.5 mL |
Each box contains 4 pens (one month’s supply at one injection per week). The pen has a gray triangular safety cover on one end and a purple injection button on the other.
You also have the option of the KwikPen — a multi-dose format that provides 4 doses per pen. Your provider and pharmacy will determine which format you receive.
The injection goes under the skin in the abdomen, thigh, or upper arm. Same day each week, any time of day, with or without food.[2]
Dosing: How It Works
Mounjaro uses the same gradual step-up approach as other GLP-1 medications, but with six dose levels instead of four — giving providers more flexibility to find the right balance between effectiveness and tolerability.
| Step | Dose | Duration | What's Happening |
|---|---|---|---|
| 1 | 2.5 mg/week | 4 weeks | Initiation only — letting your body adjust. Not a treatment dose. |
| 2 | 5 mg/week | At least 4 weeks | First maintenance dose for blood sugar control. |
| 3 | 7.5 mg/week | At least 4 weeks | Intermediate step (if 5 mg isn't enough but 10 mg feels like too big a jump). |
| 4 | 10 mg/week | At least 4 weeks | Higher maintenance dose. |
| 5 | 12.5 mg/week | At least 4 weeks | Intermediate step toward maximum. |
| 6 | 15 mg/week | Ongoing | Maximum dose. |
Key things to know:
- Each increase is 2.5 mg at a time, with at least 4 weeks between steps. That’s a gentler ramp-up than some other GLP-1 medications.
- Not everyone needs the maximum dose. Your provider will assess your response at each level. Many people get solid blood sugar control at 5 mg or 10 mg.
- The 2.5 mg starting dose is not therapeutic — it’s purely for adjustment. Don’t be concerned if nothing dramatic happens in the first month.
- If you miss a dose, take it within 4 days. If more than 4 days have passed, skip it and take the next dose on your regular day.[3]
What the Research Shows
Mounjaro was studied in the SURPASS trial program — a series of large clinical trials testing it against placebo, other diabetes medications, and even insulin. The results consistently stood out.
Blood Sugar Control
The headline numbers across the SURPASS program:
- HbA1c reduction: Up to 2.4% at the 15 mg dose — substantially more than most other diabetes medications achieve
- Patients reaching HbA1c below 7%: Up to 97% in some trials
- Patients reaching HbA1c below 5.7% (which is the non-diabetic range): Up to 46% — a number that was essentially unheard of before tirzepatide
Head-to-Head Against Semaglutide: SURPASS-2
This is the trial people ask about most. SURPASS-2 directly compared Mounjaro against Ozempic (semaglutide 1 mg) in 1,879 patients with Type 2 diabetes over 40 weeks.
Blood sugar: All three Mounjaro doses beat semaglutide. The 15 mg dose reduced HbA1c by 2.3% compared to 1.9% with semaglutide 1 mg.
Weight loss: This is where eyes widened.
| Medication | Weight Loss at 40 Weeks |
|---|---|
| Mounjaro 5 mg | 16.7 lbs (7.6 kg) |
| Mounjaro 10 mg | 20.5 lbs (9.3 kg) |
| Mounjaro 15 mg | 24.7 lbs (11.2 kg) |
| Ozempic 1 mg | 12.5 lbs (5.7 kg) |
The 15 mg dose produced more than double the weight loss of semaglutide 1 mg — in a diabetes trial, where weight loss wasn’t even the primary goal.[4]
Weight Loss in Context
Remember, these are diabetes patients, not people in a dedicated weight management trial. The Mounjaro weight loss numbers in the SURPASS diabetes trials approached what dedicated weight loss medications were achieving in their own trials — which is why the attention was so intense.
For the dedicated weight management numbers with tirzepatide, see the Zepbound page — where the SURMOUNT trials showed up to 22.5% body weight loss.
In the SURPASS-2 trial, nearly half of patients on Mounjaro 15 mg reached an HbA1c below 5.7% — the non-diabetic range. Before tirzepatide, getting that many diabetes patients to non-diabetic blood sugar levels with a single medication was considered near-impossible. Source: Frías et al., SURPASS-2, NEJM, 2021[4]
Side Effects
The side effect profile follows the same pattern as other GLP-1 medications — GI symptoms are the most common, they peak during dose escalation, and they improve over time for most people.
The Numbers (from pooled SURPASS trials)
| Side Effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | ~4% | ~12% | ~15% | ~18% |
| Diarrhea | ~4% | ~12% | ~13% | ~17% |
| Decreased appetite | ~1% | ~6% | ~9% | ~11% |
| Vomiting | ~2% | ~5% | ~6% | ~9% |
| Constipation | ~1% | ~5% | ~6% | ~6% |
| Abdominal pain | ~4% | ~5% | ~5% | ~6% |
Context that matters: The majority of GI side effects occurred during dose escalation and decreased over time. Most were mild to moderate. The percentage of people who stopped Mounjaro because of side effects was relatively low — in the single digits across trials.[5]
How It Compares to Semaglutide on Side Effects
The overall GI side effect rates with Mounjaro are comparable to — and in some dose ranges lower than — semaglutide. The gradual 2.5 mg dose increments help. In the SURPASS-2 head-to-head, GI side effects occurred in 43-44% of the semaglutide group and 33-48% of the Mounjaro groups (depending on dose), with similar rates of people stopping treatment because of them.
The Mounjaro vs. Zepbound Question
Same molecule. Same pen. Same manufacturer. Here’s what’s different:
| Mounjaro | Zepbound | |
|---|---|---|
| Approved for | Type 2 diabetes (adults + age 10+) | Weight management, obstructive sleep apnea |
| Maximum dose | 15 mg/week | 15 mg/week |
| Insurance coverage | Broad (diabetes indication) | Variable (weight management indication) |
| Year approved | 2022 | 2023 |
The same insurance dynamics apply here as with Ozempic vs. Wegovy: the diabetes-approved version (Mounjaro) generally has much better insurance coverage than the weight-management-approved version (Zepbound). If you have Type 2 diabetes and want both blood sugar control and weight loss, Mounjaro is often the practical choice.
Never use both simultaneously. They’re the same drug — doubling up would mean doubling the dose, which is dangerous.[6]
Cost and Access
What Mounjaro Costs
List price ~$1,023–$1,069/month (all doses)
Insurance + Lilly savings card As low as $25/month
No insurance coverage $499/month with Lilly savings card
Patient Assistance (uninsured) Potentially free through Lilly Cares
The Lilly Savings Card
If you have commercial insurance that covers Mounjaro, Eli Lilly’s savings card brings your copay to as little as $25 per month for a one-month supply (up to $150 in savings per fill). The card is valid through December 2026.
If your commercial insurance does NOT cover Mounjaro, the savings card can still reduce your cost to $499 per month.[7]
Who qualifies: People with commercial insurance and a prescription for an FDA-approved use. Who doesn’t: Medicare, Medicaid, TRICARE, VA, and other government insurance — federal rules prohibit manufacturer savings cards for government programs.
Medicare Coverage
Medicare Part D covers Mounjaro for Type 2 diabetes. Copays vary by plan. The Inflation Reduction Act’s annual out-of-pocket cap may help reduce costs for Medicare beneficiaries.
If You Can’t Afford It
Eli Lilly’s Lilly Cares Patient Assistance Program provides medications at no cost for eligible uninsured patients. Contact Lilly Cares at 1-800-545-6962 or visit lillycares.com.
Drug pricing changes frequently. The numbers above were current when this page was written. For the most up-to-date costs, check directly with Lilly or your pharmacy.
Storage
Before first use Keep in the fridge (36–46°F / 2–8°C).
Room temperature Up to 86°F / 30°C for up to 21 days.
Never freeze. If it freezes, throw it away.
Protect from light. Store in the original carton.
Since each pen is single-use, there’s no “days after first use” window to worry about — you use the entire pen in one injection.[8]
The Bottom Line
Mounjaro brought something genuinely new to the GLP-1 landscape: dual-action targeting of both GLP-1 and GIP pathways in one medication. The clinical results — particularly the head-to-head data against semaglutide — showed that this different approach translates to real-world differences in blood sugar control and weight loss.
If you have Type 2 diabetes and your provider has recommended Mounjaro, you’re on a medication with a strong evidence base, a flexible dosing range, and a side effect profile that’s manageable for most people. The weight loss that accompanies it — often substantial even at diabetes doses — is a meaningful bonus that goes beyond blood sugar numbers.
For the weight management story with this same molecule, the Zepbound page covers the SURMOUNT trials and what tirzepatide looks like when it’s specifically approved and dosed for weight loss.
Sources:
- Willard, F.S., et al. “Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.” JCI Insight, 2020.
- Eli Lilly. “How to Use Mounjaro.” See also: GoodRx. “What Does Mounjaro Look Like?”
- U.S. Food and Drug Administration. “Mounjaro Prescribing Information.” 2025.
- Frías, J.P., et al. “Tirzepatide versus Semaglutide Once Weekly — SURPASS-2.” NEJM, 2021.
- Eli Lilly / FDA. “Mounjaro Adverse Reactions Data.” See also: NCBl. “Tirzepatide.”
- GoodRx. “Mounjaro vs. Zepbound.”
- Eli Lilly. “Mounjaro Savings & Resources.” See also: Eli Lilly. “Mounjaro Cost Information.”
- Eli Lilly. “Mounjaro Storage and Handling.”
Want to Start Tracking Your Progress?
Printable templates designed for people on GLP-1 medications — side effect trackers, progress logs, meal planners, and more.
View Templates